These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25500937)

  • 1. The effect of TOMM40 poly-T repeat lengths on age of onset and cerebrospinal fluid biomarkers in Finnish Alzheimer's disease patients.
    Helisalmi S; Hall A; Meriläinen EH; Väisänen V; Koivisto AM; Herukka SK; Laitinen M; Soininen H; Hiltunen M
    Neurodegener Dis; 2014; 14(4):204-8. PubMed ID: 25500937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism.
    Lindqvist D; Prokopenko I; Londos E; Middleton L; Hansson O
    J Parkinsons Dis; 2016; 6(1):99-108. PubMed ID: 26756745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOMM40 poly-T repeat lengths, age of onset and psychosis risk in Alzheimer disease.
    Chu SH; Roeder K; Ferrell RE; Devlin B; DeMichele-Sweet MA; Kamboh MI; Lopez OL; Sweet RA
    Neurobiol Aging; 2011 Dec; 32(12):2328.e1-9. PubMed ID: 21820212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of TOMM40 poly-T length on gray matter volume and cognition in middle-aged persons with APOE ε3/ε3 genotype.
    Johnson SC; La Rue A; Hermann BP; Xu G; Koscik RL; Jonaitis EM; Bendlin BB; Hogan KJ; Roses AD; Saunders AM; Lutz MW; Asthana S; Green RC; Sager MA
    Alzheimers Dement; 2011 Jul; 7(4):456-65. PubMed ID: 21784354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
    Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
    Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease.
    Cruchaga C; Nowotny P; Kauwe JS; Ridge PG; Mayo K; Bertelsen S; Hinrichs A; Fagan AM; Holtzman DM; Morris JC; Goate AM;
    Arch Neurol; 2011 Aug; 68(8):1013-9. PubMed ID: 21825236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical studies of poly-T variants in the Alzheimer's disease associated TOMM40 gene.
    Hedskog L; Brohede J; Wiehager B; Pinho CM; Revathikumar P; Lilius L; Glaser E; Graff C; Karlström H; Ankarcrona M
    J Alzheimers Dis; 2012; 31(3):527-36. PubMed ID: 22596268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity.
    Maruszak A; Pepłońska B; Safranow K; Chodakowska-Żebrowska M; Barcikowska M; Zekanowski C
    J Alzheimers Dis; 2012; 28(2):309-22. PubMed ID: 22008263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOMM40 intron 6 poly-T length, age at onset, and neuropathology of AD in individuals with APOE ε3/ε3.
    Li G; Bekris LM; Leong L; Steinbart EJ; Shofer JB; Crane PK; Larson EB; Peskind ER; Bird TD; Yu CE
    Alzheimers Dement; 2013 Sep; 9(5):554-61. PubMed ID: 23183136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes.
    Chiba-Falek O; Gottschalk WK; Lutz MW
    Alzheimers Dement; 2018 May; 14(5):692-698. PubMed ID: 29524426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
    Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K
    Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.
    Varges D; Jung K; Gawinecka J; Heinemann U; Schmitz M; von Ahsen N; Krasnianski A; Armstrong VW; Zerr I
    J Alzheimers Dis; 2011; 23(4):717-26. PubMed ID: 21157024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
    Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
    Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
    Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
    Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
    J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease.
    Kester MI; van der Flier WM; Mandic G; Blankenstein MA; Scheltens P; Muller M
    J Alzheimers Dis; 2010; 20(4):1083-90. PubMed ID: 20413898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.